The Government's Own Lawyers Just Said Cannabis Can't Stay in Schedule I. The Judge Still Hasn't Ruled.

DEA released the complete official transcript of its cannabis rescheduling hearing on August 26, and buried in the procedural language is a sentence that would have been unthinkable from a federal drug agency a decade ago: government attorneys arguing, on the record, that “marijuana can no longer remain in Schedule I.”

The government’s own lawyers just wrote the strongest rescheduling argument cannabis advocates have ever gotten for free, and it still isn’t the law.

Schedule I is the government’s label for a drug with no accepted medical use and a high potential for abuse — the same category as heroin, above cocaine and methamphetamine, which sit one rung down in Schedule II specifically because federal law already recognizes a medical use for them. In April, DEA moved cannabis in FDA-approved products and cannabis covered by a qualifying state medical-marijuana license into Schedule III — a real, completed change, but a narrow one. Everything else, including all adult-use cannabis, is still Schedule I today. The August hearing and this week’s transcript are about that bigger, still-open question: the administrative law judge overseeing the case is now reviewing post-hearing briefs from both sides and is expected to issue a formal recommendation sometime in the coming weeks to months — not this week, and not automatically the government’s final word even then.

That gap between what the government’s own attorneys are willing to say in a hearing room and what’s actually binding is the whole story for anyone running a program that depends on federal cannabis policy — a facility trying to plan insurance credentialing, a case manager telling a client what’s actually true right now, a state regulator watching for the moment federal and state law finally line up. Right now, the honest answer to “is weed rescheduled” is: partially, for medical use, since April, and the rest is a transcript, not a rule.

If your program treats cannabis use disorder and you’ve been asked by a client, a family, or a referral partner whether legal status is about to change nationally, the accurate answer this week is still “not yet, and not automatically.” The April order didn’t touch banking access, didn’t touch federal employment drug-testing rules, and didn’t touch research scheduling for anything outside the FDA-approved and state-licensed lane it carved out. Broader rescheduling would eventually move on all three — but only once a judge who hasn’t ruled yet actually rules. Watch the judge’s recommendation, not this week’s transcript, for the date that actually changes anything.